Patents Issued in October 11, 2016
  • Patent number: 9463164
    Abstract: The present invention provides a tablet having improved dissolution property, which comprises (+)-3-{1-[3-(trifluoromethoxy)benzyl]piperidin-4-yl}-4-phenyl-3,4-dihydro-2(1H)-quinazolinone or a pharmaceutically acceptable salt thereof as an active component, and a production method thereof. A film-coated tablet obtained by mixing granulated particles obtained by granulating a mixture containing (a) the aforementioned active component, (b) one or more kinds of fillers selected from lactose, D-mannitol, erythritol and crystalline cellulose, (c) a cellulose-based disintegrant and (d) a water-soluble binder with a later powder containing (e) one or more kinds of fillers selected from lactose, D-mannitol and crystalline cellulose and/or (f) a cellulose-based disintegrant, forming the mixture, and applying film coating.
    Type: Grant
    Filed: January 22, 2014
    Date of Patent: October 11, 2016
    Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventors: Makiko Yanagida, Hiroyuki Nishii, Masayuki Nakazono
  • Patent number: 9463165
    Abstract: The use of a granular material which is for orally fast disintegrating tablets and comprises at least one kind of water soluble polymer and tannic acid allows production of tablets that can be produced by a simple process with simple production equipment, disintegrate fast in the mouth, and have a proper level of moldability for practical use. The at least one kind of water soluble polymer is preferably selected from the group consisting of povidone, hydroxypropyl cellulose, pullulan, a polyvinyl alcohol-polyethylene glycol graft copolymer and copolyvidone.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: October 11, 2016
    Assignee: TEIKA PHARMACEUTICAL CO., LTD.
    Inventors: Takao Shimatani, Takahiro Kawagishi
  • Patent number: 9463166
    Abstract: The invention relates to a controlled release composition comprising a combination of isosorbide dinitrate and hydralazine, such as hydralazine hydrochloride, that in operation delivers the drug in a pulsed or multi-modal manner for the treatment of angina, ischaemic heart disease, arterial hypertension and related disease conditions. Preferably, the isosorbide dinitrate and hydralazine hydrochloride can be released from the dosage form in an erodable, diffusion and/or osmotic-controlled release profile.
    Type: Grant
    Filed: February 8, 2016
    Date of Patent: October 11, 2016
    Assignee: Recro Gainesville LLC
    Inventors: Gurvinder Singh Rekhi, Richard Sidwell, Sharon Hamm
  • Patent number: 9463167
    Abstract: Disclosed is a composition comprising MZ for use as a dietary supplement or food additive for oral consumption for improving the visual performance of a human subject.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: October 11, 2016
    Assignee: Howard Foundation Holdings Limited
    Inventors: John Nolan, Stephen Beatty, James Loughman, Alan N. Howard, David Thurnham
  • Patent number: 9463168
    Abstract: The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: October 11, 2016
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), AURIS MEDICAL AG
    Inventors: Matthieu Guitton, Jean-Luc Puel, Remy Pujol, Jerome Ruel, Jing Wang
  • Patent number: 9463169
    Abstract: A formulation to increase the ratio of gastrointestinal microbiota in phylum Bacteroidetes to microbiota of Firmicutes phylum preferably includes about 20-60 mg/kg of body weight of fermentable fiber, about 10-30 mg/kg of body weight of beta glucan and about 20-60 mg/kg of body weight of blueberry extracts or any fruit or berry ingredient preparation containing similar phenolics. This formulation is preferably used to control body weight, body composition, and blood glucose regulation, preferably in humans, and is preferably administered orally, preferably twice per day.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: October 11, 2016
    Assignee: MicroBiome Therapeutics, LLC
    Inventors: Mark L. Heiman, Dean P. Stull, Justin W. Peno
  • Patent number: 9463170
    Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: October 11, 2016
    Assignee: ELCELYX THERAPEUTICS, INC.
    Inventors: Alain D. Baron, Nigel R. A. Beeley, Mark S. Fineman
  • Patent number: 9463171
    Abstract: Therapeutic ureido-sulfonamide compositions having compounds with the formula R-Q-Ar—SO2NH2 are disclosed, which compounds selectively inhibit CAIX and CAXII, and which are effective to inhibit hypoxic tumor growth, suppress metastases, and impair and deplete cancer stem cells in mammals.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: October 11, 2016
    Assignee: Welichem Biotech Inc.
    Inventors: Claudiu Supuran, Shoukat Dedhar, Paul C. McDonald, Fabrizio Carta
  • Patent number: 9463172
    Abstract: The present invention is directed to a method of treating a subject with autism spectrum disorder by administering an acetylaminopropane sulfonate.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: October 11, 2016
    Assignee: Indiana University Research & Technology Corporation
    Inventor: Craig A. Erickson
  • Patent number: 9463173
    Abstract: The present invention relates to the field of obesity. More specifically, the present invention provides methods and compositions useful in treating obesity and obesity-associated conditions. In one embodiment, a method for treating obesity in a subject comprises the step of administering an effective amount of valproic acid (VPA) or an analog, derivative or metabolite thereof to the subject.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: October 11, 2016
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Namandje Bumpus, Lindsay Avery
  • Patent number: 9463174
    Abstract: A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: October 11, 2016
    Inventor: Qinghua Wang
  • Patent number: 9463175
    Abstract: Provided is an antimalarial drug which is useful for prevention and treatment of infectious diseases caused by malaria parasites. A preventive and/or therapeutic agent for malaria, which contains, as an active ingredient, 5-aminolevulinic acid (ALA), a derivative thereof, or a pharmacologically acceptable salt thereof, is used.
    Type: Grant
    Filed: June 22, 2015
    Date of Patent: October 11, 2016
    Assignees: SBI Pharmaceuticals Co., Ltd., The University of Tokyo
    Inventors: Tohru Tanaka, Satofumi Kawata, Takeo Kohda, Motowo Nakajima, Kiyoshi Kita
  • Patent number: 9463176
    Abstract: It has now been found that after administration to a diseased person or person that is at risk for developing such disease of a neutraceutical or pharmaceutical composition that comprises a) a lipid fraction comprising at least one of docosahexaenoic acid (DHA), docosapentaenoic acid (DPA) and eicosapentaenoic acid (EPA); b) a protein fraction comprising proteinaceous material from non-human origin which provide at least cysteine and/or taurine; and c) a mineral fraction comprising at least one of manganese and molybdenum, the health of these persons improves. Membrane function of several types of mammalian cells improves, which allows efficient treatment of immune related disorders, such as allergy, autoimmune diseases, cancer, cognitive dysfunction and other diseases of the nervous system, neuropathies, such as diabetic neuropathies and neuropathic pains, neuronal damage during insulin resistance, and gut diseases and support of the development of gut and lung function during growth or recovery.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: October 11, 2016
    Assignee: N.V. Nutricia
    Inventor: Robert J. J. Hageman
  • Patent number: 9463177
    Abstract: Methods of modulating healing response to vascular injury and/or vascular scarring in a subject are provided. As such, aspects of the disclosure relate to the use of pro-resolving lipid mediators to modulate inflammation and/or restenosis of a vascular wall. Another aspect of the disclosure relates to the use of pro-resolving lipid mediators to modulate a biological activity of vascular smooth muscle cells (VSMC) or vascular endothelial cells (VEC). Pro-resolving lipid mediators that find use in the subject methods include derivatives of omega-3 polyunsaturated fatty acids and omega-6 polyunsaturated fatty acids, such as resolvins, protectins, lipoxins and maresins and their therapeutically stable analogs. Also provided are vascular devices and compositions for use in the subject methods. Such methods, devices and compositions find use in a variety of applications, including applications related to treatment of vascular injuries and vascular scarring (e.g.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: October 11, 2016
    Assignees: The Regents of the University of California, The Brigham and Women's Hospital, Inc.
    Inventors: Michael S. Conte, Charles N. Serhan, Tejal A. Desai
  • Patent number: 9463178
    Abstract: An ophthalmic solution is provided. The ophthalmic solution includes an ultraviolet-A absorber and an ultraviolet-B absorber. The ophthalmic solution has a viscosity of between about 1 and 100 cps. The ophthalmic solution can be used to absorb ultraviolet radiation in the eye.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: October 11, 2016
    Inventor: Brian J. Smith
  • Patent number: 9463179
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 11, 2016
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Patent number: 9463180
    Abstract: Methods for treating molluscum contagiosum warts include identifying a human with one or more molluscum contagiosum warts and applying an anti-infective composition to the one or more warts. The anti-infective composition comprises at least one anti-infective agent in a liquid carrier, such as an organohalide. The liquid carrier includes a tissue penetrating component for rapid penetration of the anti-infective agent into the one or more molluscum contagiosum warts. Application of the anti-infective composition to molluscum contagiosum warts causes the warts to turn black and/or fall off the skin in less than about 5 days.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 11, 2016
    Assignee: QUADEX PHARMACEUTICALS, LLC
    Inventor: B. Ron Johnson
  • Patent number: 9463181
    Abstract: The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: October 11, 2016
    Assignees: Pemix Sleep, Inc., ProCom One, Inc.
    Inventors: Susan E. Dubé, Neil B. Kavey
  • Patent number: 9463182
    Abstract: The use, as a dermatological or cosmetic ingredient, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed “dermatoporosis”, estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization in situ.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: October 11, 2016
    Assignee: THESAN PHARMACEUTICALS, INC.
    Inventor: Jean Hilaire Saurat
  • Patent number: 9463183
    Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: October 11, 2016
    Assignee: SILVERGATE PHARMACEUTICALS, INC.
    Inventors: Gerold L. Mosher, David W. Miles
  • Patent number: 9463184
    Abstract: Calcium flux agonists are used to enhance a TLR- or NOD-mediated stimulus and to so increase an immune response of a host and reduce healing time. Preferred calcium flux agonists include Ca2+ ionophores and SERCA inhibitors and are used in synergistic quantities where a ligand to a TLR or NOD receptor is present.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: October 11, 2016
    Assignee: Nant Holdings IP, LLC
    Inventors: Kayvan Niazi, Shahrooz Rabizadeh, Justin Golovato, Patrick Soon-Shiong, Anne-Laure Le Ny, Oleksandr Buzko
  • Patent number: 9463185
    Abstract: A preparation containing [3-[2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl]-5-methyl-1,2-benzisoxazol-6-yl]oxyacetic acid, [4-[3-[2-(4-trifluoromethyl)phenyl-4-isopropyl-5-thiazolyl]propionyl]-2-methylphenoxy]acetic acid or [4-[3-[2-(2-hydroxy-4-chlorophenyl)-5-isopropyl-4-oxazolyl]propionyl]-2-methylphenoxy]acetic acid, or a pharmacologically acceptable salt thereof as an active ingredient is used as an agent for promoting proliferation of meibomian gland epithelial cells or corneal epithelial cells, as well as a therapeutic agent for ocular diseases such as meibomian gland dysfunction, dry eye and the like.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: October 11, 2016
    Assignees: SENJU PHARMACEUTICAL CO., LTD., NIPPON CHEMIPHAR CO., LTD.
    Inventors: Yoshikuni Nakamura, Ikuko Hanano, Jun Inoue
  • Patent number: 9463186
    Abstract: The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Cav1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: October 11, 2016
    Assignee: Northwestern University
    Inventors: Dalton J. Surmeier, Javier Sanchez, Jaime Guzman, Enrico Zampese, Daniel Galtieri, Ema Ilijic
  • Patent number: 9463187
    Abstract: The present invention provides methods of using compounds of formula I: and salts and prodrugs thereof, wherein n, R1 and R2 are defined herein. The invention also provides certain novel compounds of formula I and pharmaceutical compositions comprising them.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: October 11, 2016
    Assignee: Ampio Pharmaceuticals, Inc.
    Inventors: David Bar-Or, Nagaraja K. R. Rao
  • Patent number: 9463188
    Abstract: Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. The osteopontin production inhibitor contains a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by Chemical Formula 1 or 2, and the dihydrodictyopyrone derivative is preferably a compound represented by Chemical Formula 3 or 4.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: October 11, 2016
    Assignees: TOHOKU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY, FUSO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Haruhisa Kikuchi, Yoshiteru Oshima, Toshio Hattori, Yuzuru Kubohara, Osamu Yamada, Jing Zhang, Yoshihisa Matsushita, Shinya Kida
  • Patent number: 9463189
    Abstract: Disclosed herein are new methods of treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and other fibrotic diseases of the liver in a subject by modulating PPAR? with sulfonyl-substituted bicyclic compounds and compositions as pharmaceuticals.
    Type: Grant
    Filed: May 14, 2013
    Date of Patent: October 11, 2016
    Assignee: BPV Holdings, LLC
    Inventors: Mausumee Guha, Paul Grint
  • Patent number: 9463190
    Abstract: Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: October 11, 2016
    Assignee: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Theresa A. Zesiewicz, Kelly L. Sullivan
  • Patent number: 9463191
    Abstract: A composition of an antitussive, a decongestant, or an antihistamine to treat upper respiratory and oral pharyngeal congestion and related symptoms in a patient.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: October 11, 2016
    Assignee: GM Pharmaceuticals, Inc.
    Inventor: Odes W. Mitchell
  • Patent number: 9463192
    Abstract: The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: October 11, 2016
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun Takeuchi, Satoshi Itadani, Kazuya Hashimura, Masahiro Ikura, Masato Higashino, Tetsuya Yasuhiro, Takeshi Nagaura
  • Patent number: 9463193
    Abstract: The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5-FU dose administered by continuous infusion in patients treated by a FOLFIRI regimen or a similar regimen, based on the 5-FU plasmatic concentration measured during the previous 5-FU continuous infusion and on a herein described decision algorithm. The present invention also relates to a method for treating a cancer patient in which the 5-FU dose administered in continuous infusion in each FOLFIRI or similar treatment cycle is optimized using the decision algorithm according to the invention.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: October 11, 2016
    Assignees: INSTITUT DE CANCEROLOGIE DE L'OUEST, UNIVERSITE D'ANGERS
    Inventors: Erick Gamelin, Michéle Boisdron-Celle, Alain Morel
  • Patent number: 9463194
    Abstract: The disclosure describes methods for treatment of patients co-infected with HIV and tuberculosis, wherein the patient receives effective amounts of elvitegravir, an antimycobacterial agent and a CYP inhibitor.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: October 11, 2016
    Assignee: Gilead Sciences, Inc.
    Inventors: Rebecca Restituto Begley, Joseph Marcello Custodio, Brian P. Kearney
  • Patent number: 9463195
    Abstract: Methods for disrupting amyloid fibrils in a subject, comprising combining an effective amount of a ?-2 microglobulin fibril disrupting compound with a medium associated with the subject, are disclosed. The invention also relates to combining the ?-2 microglobulin fibril disrupting compound ex vivo with the blood during dialysis treatment of an animal. It also relates to methods for determining which compounds are effective at disrupting amyloid fibrils in a medium.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: October 11, 2016
    Assignee: The Regents of the University of California
    Inventors: David S. Eisenberg, Melinda Balbirnie
  • Patent number: 9463196
    Abstract: The present invention relates to a once daily tablet comprising doxycycline at sub-antibiotic dose and one or more pharmaceutically acceptable excipients, wherein the tablet exhibits a reduced food effect. The invention further provides a method of treatment of rosacea by administering to a person in need thereof the doxycycline tablet with or without food. A process of preparing the tablet is also provided.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: October 11, 2016
    Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITED
    Inventors: Ravish Kumar Sharma, Pulak Kumar Metia, Ravinder Singh, Rajesh Srikrishan Shear, Anuj Kumar Fanda, Satish Kumar Jain, Romi Barat Singh, Swarna Pappu, Prabhakar Konatham, Pruthvipathy Katikaneni, Dileep Jami
  • Patent number: 9463197
    Abstract: A method for treating an abnormal polyglutamine-mediated disease is disclosed, which comprises: administering a pharmaceutical composition comprising a trehalose-based compound to a subject in need. Additionally, the pharmaceutical composition optionally further comprises a trehalase inhibitor.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: October 11, 2016
    Assignee: NATIONAL TAIWAN NORMAL UNIVERSITY
    Inventors: Guey-Jen Lee-Chen, Hsiu-Mei Hsieh, Guan-Chiun Lee
  • Patent number: 9463198
    Abstract: Compositions comprising glucopyranosyl lipid adjuvant (GLA) and methods for reducing or preventing the formation of cancer metastasis utilizing same are provided. The compositions may be formulated for local-regional delivery. The compositions may be substantially devoid of a cancer antigen. The treatment with GLA may be combined with treatment with a COX2 inhibitor and a beta-adrenergic blocker.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: October 11, 2016
    Assignee: Infectious Disease Research Institute
    Inventors: Shamgar Ben-Eliyahu, Pini Matzner, Steven G. Reed
  • Patent number: 9463199
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Grant
    Filed: March 23, 2005
    Date of Patent: October 11, 2016
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann
  • Patent number: 9463200
    Abstract: The present invention relates to modified oligonucleotides of 5-50 nucleotide residues, wherein at least 25% of the nucleotides are independently modified at the 2? position to comprise the structure of formula (I), wherein base is a purine or pyrimidine moiety; and R1, R2, R3, R4, p and q are as defined in the description. The modified oligonucleotides comprising said structures are useful as medicaments for enhancement of drug uptake in oligonucleotide based therapy in humans and animals.
    Type: Grant
    Filed: February 28, 2014
    Date of Patent: October 11, 2016
    Assignee: OLIGOMER SCIENCES AB
    Inventors: Roger Strömberg, Dmytro Honcharenko, Stefan Milton
  • Patent number: 9463201
    Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: October 11, 2016
    Assignee: M.G. THERAPEUTICS LTD
    Inventors: Yair Alster, Omer Rafaeli, K. Angela Macfarlane, Cary Reich, Shimon Amselem, Doron Friedman
  • Patent number: 9463202
    Abstract: A dialysis acid precursor assembly including a dialysis acid precursor composition of dry components including anhydrous glucose, a dry acid, a magnesium chloride 4.5-hydrate (MgCl2.4.5H2O) and a potassium salt or calcium salt, and a moisture-resistant container with a water vapor transmission rate less than 0.2 g/m2/d at 38° C./90% RH, wherein the dialysis acid precursor composition is sealed within the container.
    Type: Grant
    Filed: December 11, 2012
    Date of Patent: October 11, 2016
    Assignee: Gambro Lundia AB
    Inventors: Olof Jansson, Jens Gustafsson, Torbjorn Linden
  • Patent number: 9463203
    Abstract: Regenerative cells present in adipose tissue are used to treat patients, including patients with musculoskeletal diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, regenerative cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic musculoskeletal benefit.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: October 11, 2016
    Assignee: Cytori Therapeutics, Inc.
    Inventors: Marc H. Hedrick, John K. Fraser, Susan L. Riley, Ronda E. Schreiber
  • Patent number: 9463204
    Abstract: The object of the invention is to provide a technique of suppressing tumorigenesis in IPS cells and inducing differentiation into target differentiated cells. In use of a statin and a differentiation inducer, iPS cells are differentiated into target differentiated cells, whereby iPS cells can be differentiated into differentiated cells in which tumorigenesis is suppressed.
    Type: Grant
    Filed: December 27, 2012
    Date of Patent: October 11, 2016
    Assignee: Osaka University
    Inventor: Hiroshi Egusa
  • Patent number: 9463205
    Abstract: The present invention provides novel drug discovery platforms and methods for treating type I diabetes.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: October 11, 2016
    Assignee: BioCrine AB
    Inventors: Per-Olof Berggren, Alejandro Caicedo
  • Patent number: 9463206
    Abstract: Described herein are tissue grafts produced by contacting dehydrated placental tissue grafts with a cross-linking agent. The tissue grafts described herein provide barrier and prevent the migration of a bioactive agent from the wound. Thus, the tissue grafts enhance wound healing while preventing the undesirable migration of a bioactive agent from the wound. Methods for making and using the cross-linked grafts are also described herein.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: October 11, 2016
    Assignee: MiMedx Group, Inc.
    Inventors: Tom Koob, John Daniel, Randall Spencer
  • Patent number: 9463207
    Abstract: A method for preparing placenta membrane tissue grafts for medical use, includes obtaining a placenta from a subject, cleaning the placenta, separating the chorion tissue from the amniotic membrane, mounting a selected layer of either the chorion tissue or the amniotic membrane onto a drying fixture, dehydrating the selected layer on the drying fixture, and cutting the selected layer into a plurality of tissue grafts. Preferably, the drying fixture includes grooves or raised edges that define the outer contours of each desired tissue graft, after they are cut, and further includes raised or indented logos that emboss the middle area of the tissue grafts during dehydration and that enables an end user to distinguish the top from the bottom side of the graft. The grafts are comprised of single layers of amnion or chorion, multiple layers of amnion or chorion, or multiple layers of a combination of amnion and chorion.
    Type: Grant
    Filed: May 22, 2014
    Date of Patent: October 11, 2016
    Assignee: MiMedx Group, Inc.
    Inventor: John Daniel
  • Patent number: 9463208
    Abstract: This document discusses, among other things, receiving a plurality of donor fecal samples from a plurality of donors and storing and indexing each respective donor fecal samples using at least one characteristic of the respective donor fecal sample. In an example, the donor fecal sample can be screened and processed for subsequent use in fecal bacteriotherapy to displace pathogenic or undesired organisms in the digestive track of a patient with healthy or desirable gut micriobiota.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: October 11, 2016
    Assignee: REBIOTIX, INC.
    Inventor: Edwin J. Hlavka
  • Patent number: 9463209
    Abstract: The present invention relates to an extract from bacterial strains, such as Staphylococcus, Moraxella, Klebsiella, Streptococcus, and Haemophilus. The extract is useful as a treatment for indications such as respiratory disorders, compositions comprising the extract, and processes of making the extract from media that do not pose a risk of prion diseases.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: October 11, 2016
    Assignee: OM PHARMA SA
    Inventors: Jacques Alain Bauer, Marco Salvagni, Jean-Pierre Leon Vigroux, Laetitia Chalvet, Carlo Chiavaroli
  • Patent number: 9463210
    Abstract: A method for alleviating cravings and discomfort of a user due to nicotine addiction upon immediate cessation of tobacco by said user, comprising the steps of inhaling, upon commencement of a nicotine craving episode, for about 10 minutes, between about 3 to 5 drops of rosemary essential oil, wherein said rosemary essential oil is sprinkled on an apposite vaporizer pad, orally ingesting between about 250 mg to 500 mg of niacinamide, orally ingesting between about 200 mg to 300 mg of sarcosine, orally ingesting between about 300 mg to 600 mg of red Korean ginseng extract, and orally ingesting about 500 mg of soy lecithin.
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: October 11, 2016
    Inventor: Antonino Cavallaro
  • Patent number: 9463211
    Abstract: The subject patent discloses a method for treating intertrigo on the underside of a female breasts which comprises (1) applying a skin salve to the underside of the female breasts, wherein the female breasts are dry, and wherein the skin salve is comprised of (i) petrolatum, (ii) from 11 weight percent to 60 weight percent beeswax, and (iii) from 0.25 weight percent to 10 weight percent peppermint oil, wherein the skin salve has a viscosity at 25° C. which is within the range of 11 Pa·s to 15 Pa·s at a shear rate of 35 l/s, and (2) allowing the skin salve to remain in contact with female breasts for a period of at least 4 hours.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: October 11, 2016
    Inventor: Teresa D. Carter
  • Patent number: 9463212
    Abstract: A method of reducing the number of microorganisms entering the nose and proliferating in the nasal cavity including application of a solution of an antimicrobial, antiviral and antifungal composition to the anterior vestibular region of the nares. The antimicrobial, antiviral and antifungal solution includes ethyl alcohol as an active ingredient. Various embodiments may also include one or more of the following additional ingredients: orange oil, coconut oil; soy oil; emu oil; grapefruit seed extract; glycine soja; simmondsia chinensis (Jojoba); lauric acid; aloe vera; and a preservative, such as benzalkonium chloride and vitamin E.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: October 11, 2016
    Assignee: GLOBAL LIFE TECHNOLOGIES CORP.
    Inventor: John A. Willimann
  • Patent number: 9463213
    Abstract: The use of degarelix in the treatment of endometriosis, in particular in the treatment of endometriotic ovarian cysts and recurrent endometriotic lesions following surgery and in the treatment of endometriosis and/or endometriotic ovarian cysts in patients who plan to undergo assisted reproduction, is described, wherein this treatment is performed before the patients are subjected to assisted reproduction; degarelix is administered for this purpose as a single dose of 80-120 mg, preferably 80 mg, subcutaneously.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: October 11, 2016
    Inventors: Fabio Scarpellini, Marco Sbracia